Vaccines and Infectious Diseases · eu
Flu vaccine OVX836 misses Phase 2 efficacy target as Osivax shifts to combination with seasonal vaccines
A trial involving 2,850 participants failed to confirm OVX836’s protective benefit. Osivax will advance combination development through two pharmaceutical partnerships, but whether it can add protection to existing flu vaccines requires new clinical evidence.
For flu vaccines to provide broader protection, new immune approaches must still be tested against the actual risk of illness. Osivax announced on October 15 that its vaccine candidate OVX836 did not meet the prespecified efficacy endpoint in a Phase 2b trial. The company will next advance a development strategy combining it with existing seasonal flu vaccines to explore the possibility of increasing protection.
The placebo-controlled trial enrolled 2,850 adults. Estimated vaccine efficacy for OVX836 was 24%, but the result was not statistically significant. This figure estimates the reduction in risk relative to the placebo group; it cannot be interpreted as confirming 24% protection. Based on this analysis, the trial does not provide sufficient evidence to confirm that the vaccine can reduce the risk of illness.
OVX836 is designed to target the relatively conserved nucleoprotein inside the flu virus, with the aim of inducing cellular immunity to provide protection across viral strains. This differs from the approach of seasonal vaccines, which primarily target viral surface antigens, and provides the scientific rationale for combining the two. However, whether the immune response can translate into measurable clinical benefit is the unresolved question left by these results.
Osivax said it will advance the combination of OVX836 with existing seasonal flu vaccines through two pharmaceutical partnerships. This makes the development question more specific: Can adding OVX836 reduce flu cases more than a seasonal vaccine alone? The results of this comparison with placebo cannot directly answer that question.
Interpreting this setback also requires complete case counts, confidence intervals for the efficacy estimate, and data by group. Missing the primary endpoint means that the prespecified core efficacy claim was not supported. It does not prove that all uses are ineffective, but neither does it support the inference that switching to a combination strategy will succeed. These results also cannot be used to assess the efficacy of existing seasonal vaccines.
The key next step is to confirm the combination’s additional benefit through appropriately controlled trials and assess safety and tolerability. For vaccine development aimed at broadening flu protection, complementary immune mechanisms offer a direction for research. Whether they can actually reduce the burden of disease remains a question for clinical results to answer.